Raras
Buscar doenças, sintomas, genes...
Reação medicamentosa com eosinofilia e sintomas sistêmicos
ORPHA:139402CID-10 · T78.4CID-11 · EH65DOENÇA RARA

A síndrome DRESS (Drug Rash with Eosinophilia and Systemic Sintomas) é uma reação de hipersensibilidade caracterizada por erupção cutânea generalizada, febre, eosinofilia, linfocitose e envolvimento visceral (hepatite, nefrite, pneumonite, pericardite e miocardite) e, em alguns pacientes, reativação do vírus do herpes humano 6.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A síndrome DRESS (Drug Rash with Eosinophilia and Systemic Sintomas) é uma reação de hipersensibilidade caracterizada por erupção cutânea generalizada, febre, eosinofilia, linfocitose e envolvimento visceral (hepatite, nefrite, pneumonite, pericardite e miocardite) e, em alguns pacientes, reativação do vírus do herpes humano 6.

Publicações científicas
1.362 artigos
Último publicado: 2026 Apr 9

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Cobertura mínimaScore: 5%
Triagem neonatal (Fase 5)CID-10: T78.4
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
4 sintomas
🫃
Digestivo
3 sintomas
🫘
Rins
3 sintomas
🩸
Sangue
3 sintomas
🛡️
Imunológico
2 sintomas
📏
Crescimento
2 sintomas

+ 7 sintomas em outras categorias

Características mais comuns

90%prev.
Encefalite infecciosa
Muito frequente (99-80%)
90%prev.
Erupção cutânea
Muito frequente (99-80%)
90%prev.
Mácula
Muito frequente (99-80%)
90%prev.
Perda de peso
Muito frequente (99-80%)
90%prev.
Tireoidite
Muito frequente (99-80%)
90%prev.
Febre
Muito frequente (99-80%)
28sintomas
Muito frequente (12)
Frequente (4)
Ocasional (12)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 28 características clínicas mais associadas, ordenadas por frequência.

Encefalite infecciosaInfectious encephalitis
Muito frequente (99-80%)90%
Erupção cutâneaSkin rash
Muito frequente (99-80%)90%
MáculaMacule
Muito frequente (99-80%)90%
Perda de pesoWeight loss
Muito frequente (99-80%)90%
TireoiditeThyroiditis
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.362PubMed
Últimos 10 anos200publicações
Pico2025155 papers
Linha do tempo
2026Hoje · 2026🧪 2008Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Triagem neonatal (Teste do Pezinho)

👶
Teste: qPCR para deleção de SMN1 em sangue seco
Fase 5 do PNTNpending
Incidência no Brasil: 1:10.000

A triagem neonatal permite diagnóstico precoce e início imediato do tratamento.

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Reação medicamentosa com eosinofilia e sintomas sistêmicos

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

9 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1.167 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.167

#1

Correction: The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.

Cureus2026 Mar

[This corrects the article DOI: 10.7759/cureus.104474.].

#2

The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.

Cureus2026 Mar

Drug hypersensitivity reactions are a clinically significant and potentially preventable cause of hospital admission, treatment interruption, and drug-related mortality worldwide. Within severe cutaneous adverse reactions (SCARs), a group that includes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS), DRESS stands out because of its delayed onset, multi-organ involvement, and frequent diagnostic uncertainty. Allopurinol is a commonly prescribed medication for hyperuricemia, but in rare cases, it can trigger DRESS. This systematic review was conducted to comprehensively summarize the demographic characteristics, clinical manifestations, diagnostic features, management strategies, and outcomes of reported cases of allopurinol-induced DRESS syndrome. Available case reports and case series were analyzed to consolidate patient characteristics, patterns of organ involvement, treatment approaches, and clinical outcomes. The findings indicate that allopurinol-induced DRESS most often presents with cutaneous manifestations and systemic involvement, most commonly affecting the liver and kidneys, and is associated with considerable morbidity and mortality despite treatment. These results emphasize the importance of early recognition, prompt drug discontinuation, and cautious prescribing of allopurinol, particularly in high-risk populations.

#3

A case of steroid-induced mania following lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS): a cautionary tale.

SAGE open medical case reports2026

Drug reaction with eosinophilia and systemic symptoms is a severe cutaneous adverse reaction frequently associated with lamotrigine, an antiepileptic drug also used to treat bipolar disorder. Although a mainstay of therapy for drug reaction with eosinophilia and systemic symptoms is oral corticosteroids, steroids should be used with caution in patients with bipolar disorder, as mania is a well-known drug side effect. We present a case of a 21-year-old female patient with bipolar disorder who was treated with prednisone for lamotrigine-induced drug reaction with eosinophilia and systemic symptoms, and subsequently experienced steroid-induced mania, exacerbated by an unopposed antidepressant medication. This resulted in involuntary hospital admission under psychiatry, which was profoundly distressing for the patient. We present this case as a reminder to screen for risk of mania in patients receiving systemic corticosteroids, and to carefully assess concurrent antidepressant use when discontinuing mood stabilizers like lamotrigine.

#4

Tofacitinib Rescue for Refractory Drug-Induced Liver Injury With Severe DRESS: A Prospective Proof-of-Concept Study.

Liver international : official journal of the International Association for the Study of the Liver2026 Apr

Drug-induced liver injury (DILI) with severe DRESS carries high mortality, yet rescue therapies for corticosteroid-refractory cases remain undefined. We hypothesized that JAK inhibition could reverse refractory liver injury by targeting the underlying cytokine storm. In this prospective proof-of-concept study, consecutive patients with severe DRESS-associated DILI refractory to corticosteroids (persistent/worsening liver injury) received oral tofacitinib rescue. Key assessments were the normalisation of liver biochemistries. Despite initial corticosteroids, all four patients exhibited progressive severe injury (median peak ALT 1126 U/L). Tofacitinib rapidly reversed liver injury in all cases. Transaminases normalised or near-normalised (median: 48 days), total bilirubin normalised, and cutaneous symptoms resolved completely. Notably, baseline positive autoantibodies seroconverted to negative. No severe adverse events occurred (median follow-up: 274 days). Tofacitinib shows promise as a rescue strategy for corticosteroid-refractory DILI with severe DRESS. The rapid recovery underscores the JAK-STAT pathway's pathogenic role in this setting.

#5

A Diagnostic Pitfall: Carbamazepine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Masquerading As Angiotensin-Converting Enzyme Inhibitor Angioedema.

Cureus2026 Mar

Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a severe, multiorgan, delayed hypersensitivity reaction with significant morbidity. Diagnosis is often delayed due to its mimicry of other conditions. We present the case of a 69-year-old Hispanic male with hypertension and stage two chronic kidney disease who developed trigeminal neuralgia and was started on carbamazepine. Approximately seven weeks later, he presented with a generalized rash, angioedema, and mucosal swelling, initially attributed to his concurrent lisinopril therapy. Despite discontinuation of lisinopril and treatment with corticosteroids and antihistamines, his condition progressed with new systemic symptoms, including paresthesia, dysgeusia, polydipsia, polyuria, and weight loss. The progression of symptoms despite this intervention was the pivotal diagnostic clue. Hospital admission revealed marked eosinophilia (8.9 percent), mild transaminitis, and a diffuse erythrodermic rash involving more than 90 percent of his body surface area. A diagnosis of probable DRESS syndrome (RegiSCAR score six) secondary to carbamazepine was made. Immediate discontinuation of carbamazepine and initiation of intravenous corticosteroids led to rapid clinical and laboratory improvement. He was discharged on a prolonged oral steroid taper with complete resolution at follow-up. This case underscores the critical importance of considering DRESS in any patient with a rash and systemic symptoms occurring two to eight weeks after initiation of a high-risk drug, even in the presence of other potential culprits. It highlights that clinical progression despite withdrawal of one suspected agent should prompt urgent re-evaluation for an alternative etiology, such as DRESS.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC679 artigos no totalmostrando 194

2026

The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.

Cureus
2026

A case of steroid-induced mania following lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS): a cautionary tale.

SAGE open medical case reports
2026

Tofacitinib Rescue for Refractory Drug-Induced Liver Injury With Severe DRESS: A Prospective Proof-of-Concept Study.

Liver international : official journal of the International Association for the Study of the Liver
2026

A Diagnostic Pitfall: Carbamazepine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Masquerading As Angiotensin-Converting Enzyme Inhibitor Angioedema.

Cureus
2026

Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database.

The Journal of antimicrobial chemotherapy
2026

Hematologic Patterns in Differentiating DRESS From Morbilliform Drug Eruptions: A Preliminary Investigation.

Dermatitis : contact, atopic, occupational, drug
2026

Soluble Fas Ligand, an overlooked target of therapy in dermatological and non-dermatological conditions.

The Journal of dermatological treatment
2025

Clopidogrel-induced drug-induced hypersensitivity syndrome following percutaneous coronary intervention: a case report of therapeutic dilemma and management strategy.

Frontiers in pharmacology
2026

Drug Reaction with Eosinophilia and Systemic Symptoms in the Electronic Medical Record.

International archives of allergy and immunology
2026

Insights into Severe Cutaneous Adverse Drug Reactions: A 5-Year Retrospective Analysis of Stevens- Johnson Syndrome- Toxic Epidermal Necrolysis and Drug Rash with Eosinophilia and Systemic Symptoms.

Indian dermatology online journal
2026

[Drug-induced hypersensitivity reactions : Pulmonary manifestations and radiological characteristics].

Radiologie (Heidelberg, Germany)
2026

Severe DRESS syndrome with hemophagocytic lymphohistiocytosis and cryptococcal meningitis: a case report and diagnostic challenge.

Frontiers in immunology
2026

Possible drug reaction with eosinophilia and systemic symptoms after spironolactone therapy for clinical hyperandrogenism: a case report.

F&amp;S reports
2026

Double Jeopardy: Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Complicated by Valproate Hepatotoxicity.

Cureus
2026

Racial Disparities in Severe Cutaneous Adverse Reactions: A Report of Two Cases on Preventable Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Prescription Errors Through Medication Stewardship.

Cureus
2026

JAK1 or JAK1/2 inhibitors in Drug Reaction with Eosinophilia and Systemic Symptoms: A case series.

Clinical and experimental dermatology
2026

Navigating a Dual Hyperinflammatory State: Overlap of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) and Secondary Hemophagocytic Lymphohistiocytosis (HLH) in a Child.

Cureus
2026

Cyclosporine use in paediatric dermatologic conditions: A comprehensive review of therapeutic applications.

British journal of clinical pharmacology
2026

Baricitinib for traditional Chinese medicine-induced drug reaction with eosinophilia and systemic symptoms: a case report.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2026

Atypical presentation of DRESS/DiHS mimicking an acquired ichthyosis: A case report of bortezomib-induced severe erythroderma in multiple myeloma.

SAGE open medical case reports
2025

Real-World Data on Severe Cutaneous Adverse Reactions to Drugs.

Pharmaceuticals (Basel, Switzerland)
2026

Clinical and prognostic implications of erythema multiforme-like lesions in patients with DRESS: A prospective case-control study.

Clinical and experimental dermatology
2026

Symptomatic Hypercalcemia with Vomiting in a Pediatric Patient with Graves' Disease.

Journal of clinical research in pediatric endocrinology
2026

Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome in a patient with previous nephrectomy: a case report.

Journal of medical case reports
2026

Drug Reaction with Eosinophilia and Systemic Symptoms Following Antibiotic Cement Spacer Placement: A Case Report.

JBJS case connector
2025

Severe cutaneous adverse drug reactions due to antituberculosis drugs and their management.

Northern clinics of Istanbul
2025

A Complex Diagnostic Challenge of Dual Antibiotic-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome With Multiorgan Involvement.

Cureus
2026

Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Induced by Abiraterone: Evidence From a Positive Rechallenge.

American journal of therapeutics
2026

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS Syndrome) Manifesting With Pseudolymphoma Multisystemic Organ Involvement.

Clinical case reports
2025

Antibiotic-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) in a Young Male: A Case Report of Recurrence Without Organ Involvement.

Cureus
2025

Gemcitabine-Induced Drug Rash With Eosinophilia and Systemic Symptoms (DRESS Syndrome): A Case Report.

Cureus
2025

Cefadroxil-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome After Double Mastectomy for Ductal Carcinoma In Situ: A Case Report.

Cureus
2025

DRESS syndrome in a patient with rheumatoid arthritis: Navigating the intersection of drug-induced hypersensitivity and immune-mediated inflammation.

BMJ case reports
2025

Mycoplasma Rash With Eosinophilia and Systemic Symptoms: A Report of Two Cases.

Pediatric dermatology
2025

Corrigendum to: A Rare Clinical Course in Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: Lung Involvement.

Pediatric allergy, immunology, and pulmonology
2025

Successful evaluation and management of insulin hypersensitivity reactions.

Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology
2026

Cheilitis: a comprehensive review and a new clinical classification proposal. Part 1: Isolated cheilitis.

Italian journal of dermatology and venereology
2026

Examination of HLA-DRB1*15-linked Candidate Antigens in Still Disease With and Without Lung Disease and Drug-Associated Immune Reactions.

The Journal of rheumatology
2025

DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Is More: A Rare Case of Acalculous Cholecystitis.

ACG case reports journal
2026

Association between human herpesvirus reactivations and the severity of maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms: a retrospective comparative study.

The British journal of dermatology
2025

Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database.

Frontiers in pharmacology
2026

Regarding "Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Induced by Meropenem in a Patient Receiving Avelumab and Subsequent Flare-up".

Journal of investigational allergology &amp; clinical immunology
2026

Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.

International journal of clinical pharmacy
2025

Incidence and clinical patterns, severity and preventability of cutaneous adverse drug reactions among hospitalized patients in a tertiary centre.

The Medical journal of Malaysia
2025

DRESS Syndrome Mimicking Postoperative Cholestasis: A Case Report.

Clinical medicine insights. Case reports
2025

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Caused by Pola-R-CHOP: A Case Report.

Cureus
2025

A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.

Scientific reports
2025

Case Report: Praziquantel-induced flare-up reaction in a rare case of diclofenac-induced probable DRESS comorbid with acute clonorchiasis: diagnostic and therapeutic challenges.

Frontiers in medicine
2025

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Due to Trimethoprim: A Case Report.

Cureus
2025

DRESS syndrome with cerebral vasculitis provoked by piperacillin/tazobactam: a case report.

Acta neurologica Belgica
2025

Skin-adverse drug reactions in the elderly: An underestimated and avoidable issue.

Annales de dermatologie et de venereologie
2026

Prevalence and patient-level factors associated with common antibiotic allergy labels among patients undergoing hematopoietic stem cell transplants: a cross-sectional study.

The journal of allergy and clinical immunology. In practice
2025

HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US.

JAMA dermatology
2025

Postoperative Staphylococcal Toxic Shock Syndrome in a Patient Following Right Knee Fracture Repair: A Case Report.

Cureus
2025

A Case of Drug-Induced Lung Injury With Systemic Features Resembling DRESS Caused by Saiko-Ka-Ryukotsu-Borei-To and Goreisan.

Respirology case reports
2026

Cotrimoxazole-Induced Drug-Induced Hypersensitivity Syndrome/Drug Reaction With Eosinophilia and Systemic Symptoms With Persistent Human Herpesvirus-6 DNA Detection and Flare Without Elevated TARC Levels.

The Journal of dermatology
2025

Human Herpesvirus 6 in Acute Liver Failure: Leading Role, Supporting Actor or Innocent Bystander? A Case Series, Narrative Review and Management Algorithm Proposal.

Journal of viral hepatitis
2026

Biologic therapies for dermatologic emergencies: A comprehensive review.

Journal of the American Academy of Dermatology
2025

Undressing DReSS as p-i mediated disease.

Allergology international : official journal of the Japanese Society of Allergology
2025

Eosinophilic Myocarditis Treated with IL-5 Blockade: An Integrated Case Report and Literature Review.

Journal of clinical medicine
2025

An infant with drug reaction with eosinophilia and systemic symptoms caused by phenobarbital and amoxicillin: A case report.

Medicine
2025

Minocycline-induced DRESS: could dosage in relation to body fat mass be a contributing factor?

Frontiers in pharmacology
2025

Successful Management of Oxacillin-Induced Eosinophilic Myocarditis and Review of the Literature.

JACC. Case reports
2025

Drug Reaction with Eosinophilia and Systemic Symptoms Secondary to Ethambutol.

Journal of Brown hospital medicine
2025

Sulfasalazine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient With Rheumatoid Arthritis.

Cureus
2025

A Preventable Adverse Reaction: Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Following Allopurinol Use for Asymptomatic Hyperuricemia.

Cureus
2025

Clindamycin-Induced Dermatitis and the Sparing Phenomenon: A Case Report.

Cureus
2025

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) caused by niraparib: a novel antineoplastic agent.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
2025

[DRESS syndrome associated with levetiracetam use in a pediatric patient. A case report].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
2025

[Diosmin-hesperidin-induced DRESS syndrome: immune reactivation by herpesvirus].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
2025

Association of HLA-B*53 With DRESS Syndrome in Patients Treated With Raltegravir: Two Case Reports and a Literature Review.

Basic &amp; clinical pharmacology &amp; toxicology
2025

Carbamazepine-Induced Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Cureus
2026

Case series: Drug reaction with eosinophilia and systemic symptoms (DRESS).

Tropical doctor
2026

Long-term morbidity and quality of life in survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.

The British journal of dermatology
2025

Severe Cutaneous Adverse Reaction to Intraperitoneal Vancomycin: A Case of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) Syndrome.

Cureus
2025

Rucaparib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome.

Cureus
2025

The association of class II HLA alleles with tuberculosis-associated immune reconstitution inflammatory syndrome.

PLoS pathogens
2026

Drug reaction with eosinophilia and systemic symptoms syndrome in association with novel antineoplastic pharmacotherapy: Characterizing reported clinical patterns and outcomes utilizing the Food and Drug Administration Adverse Event Reporting System database.

Journal of the American Academy of Dermatology
2025

Emapalumab for Maladaptive Interferon-γ-Mediated Inflammation in Drug Reaction With Eosinophilia and Systemic Symptoms Complicating First-Line Antituberculosis Therapy.

Pediatric blood &amp; cancer
2025

Summary of the 12th International Conference on Human Herpesviruses-6A, -6B, and -7.

Journal of medical virology
2025

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Following Conversion Surgery for Esophageal Cancer: A Case Report.

Cureus
2025

Afebrile vancomycin-induced delayed hypersensitivity suggestive of incomplete drug rash with eosinophilia and systemic symptoms syndrome: a case report.

Journal of medical case reports
2025

Seasonality and Trends in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Before and During the COVID-19 Pandemic: A Pharmacovigilance Study.

medRxiv : the preprint server for health sciences
2025

A Rare Clinical Course in Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: Lung Involvement.

Pediatric allergy, immunology, and pulmonology
2025

Long-Term Safety of Anti-Interleukin-1 Medications in Children with Rheumatic Diseases: a Systematic Review.

Paediatric drugs
2025

The role of skin testing, drug challenge and IFN-γ ELISpot in delayed hypersensitivity to iodinated contrast media.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
2025

Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.

Virchows Archiv : an international journal of pathology
2025

Differentiating between a prasugrel-induced hypersensitivity reaction and an atorvastatin-induced DRESS syndrome in the post-percutaneous coronary intervention setting.

JAAD case reports
2025

HLA-B Alleles With Shared Peptide Binding Specificities Define Global Risk of Co-trimoxazole-Induced Severe Cutaneous Adverse Drug Reactions.

The journal of allergy and clinical immunology. In practice
2025

Clinical manifestations, diagnostic criteria, and treatment outcomes of minocycline-associated DRESS syndrome: a comprehensive exploration of published cases.

Frontiers in pharmacology
2025

Acute Kava (Piper Methysticum) Dermatitis With Drug Reaction With Eosinophilia and Systemic Symptoms-Like Features and Sebotropic Inflammation: A Case Series.

The American Journal of dermatopathology
2025

Anaphylaxis to Penicillin: Harvesting Insights From the Food and Drug Administration's Adverse Event Reporting System.

The journal of allergy and clinical immunology. In practice
2025

Drug Provocation Testing in Allergological Work-Up of DRESS: A Retrospective Real-Life Experience From a Specialist Centre.

Contact dermatitis
2025

Severe cutaneous adverse reactions associated with novel antiandrogens: A disproportionality analysis of three databases.

International journal of cancer
2025

Benralizumab in Corticosteroid-Refractory Drug Reaction With Eosinophilia and Systemic Symptoms: A Case Report.

Cureus
2025

A Case of Allopurinol-Induced Drug Reaction with Eosinophilia and Systemic Symptoms in a Patient With Polycystic Kidney Disease and Chronic Kidney Disease.

WMJ : official publication of the State Medical Society of Wisconsin
2025

Empagliflozin-related DRESS syndrome.

European heart journal. Case reports
2025

Development and validation of prognostic models using novel inflammatory markers for drug reactions with eosinophilia and systemic symptoms: An international multicenter cohort study.

Journal of the American Academy of Dermatology
2025

Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN: An Analysis of FAERS.

medRxiv : the preprint server for health sciences
2025

Safety of Proton Pump Inhibitor in Paediatrics: A Study Based on EudraVigilance Data.

Fundamental &amp; clinical pharmacology
2025

X-linked lymphoproliferative syndrome type 1 presenting as DRESS-HLH overlap syndrome.

BMJ case reports
2025

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Induced by Meropenem in a Patient Receiving Avelumab and Subsequent Flare-Up.

Journal of investigational allergology &amp; clinical immunology
2025

Clinical diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in children: An EAACI position paper.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2025

Carbamazepine-induced acute pancreatitis: rare manifestation of drug reaction with eosinophilia and systemic symptoms syndrome.

BMJ case reports
2026

A cross-sectional analysis of inflammatory markers as a severity and prognostic indicator in severe cutaneous adverse drug reactions.

Indian journal of dermatology, venereology and leprology
2025

[DRESS syndrome due to antituberculosis drugs. Review and comments].

Medicina
2025

Deciphering Immune Endotypes Within Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Allergy
2025

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Following Initiation of Sulfasalazine for Ulcerative Colitis: A Yearlong Clinical Challenge.

Case reports in gastrointestinal medicine
2025

Management of patients with tuberculosis medication-induced drug reaction with eosinophilia and systemic symptoms.

Current opinion in allergy and clinical immunology
2025

Carbamazepine-Induced DRESS Syndrome During Epstein-Barr Virus Reactivation in an Adolescent.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
2026

Standardization of Electronic Medical Record Documentation Improves Hospitalist Communication in Drug Reaction With Eosinophilia and Systemic Symptoms.

International journal of dermatology
2025

Co-Sensitization After Single-Dose Antibiotic Exposure During Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): The Role of Repeat Drug Patch Testing.

Contact dermatitis
2025

Drug Reaction With Eosinophilia and Systemic Symptoms in Children.

JAMA dermatology
2024

Drug reaction with eosinophilia and systemic symptoms (DRESS)with anti-tuberculosis drugs, a rare and serious complication.

Dermatology online journal
2025

Accelerated Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in Response to TMP-SMX: A Case Report.

The American journal of case reports
2025

Immune phenotyping impacts on management of severe cutaneous adverse reaction.

Current opinion in allergy and clinical immunology
2025

DRESS Syndrome in Patients With Drug-Induced Liver Injury: Characteristics and HLA Risk Factors.

The American journal of gastroenterology
2025

HLA-B Alleles with Shared Peptide Binding Specificities Define Global Risk of Cotrimoxazole-induced SCAR.

medRxiv : the preprint server for health sciences
2025

DRESS syndrome secondary to phenytoin: a case report and review of the literature.

Annals of medicine and surgery (2012)
2025

Concurrent acute interstitial nephritis with acute pyelonephritis in DRESS syndrome: a rare case report.

Annals of medicine and surgery (2012)
2025

Updates in the pathogenesis of SJS/TEN.

Allergology international : official journal of the Japanese Society of Allergology
2025

DRESS Syndrome with Cold Agglutinins: An Unusual Immune Response to Anticonvulsants.

Current drug safety
2025

PD-1 monoclonal antibody (Tislelizumab)-induced DRESS syndrome in an intrahepatic cholangiocarcinoma patient with FGFR3 mutation and elevated IgG4:A case report.

Clinical immunology (Orlando, Fla.)
2025

Rapid-onset drug reaction with eosinophilia and systemic symptoms (DReSS) in children: a scoping review.

Archives of dermatological research
2025

Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis.

British journal of clinical pharmacology
2025

Drug Reaction With Eosinophilia and Systemic Symptoms and Severe Drug-Induced Liver Injury After Off-Label Zonisamide Use for Weight Loss.

ACG case reports journal
2025

Elucidating CD4+ and CD8+ T-cell involvement in patients with vancomycin-induced DRESS.

Toxicological sciences : an official journal of the Society of Toxicology
2025

Vancomycin-Induced DRESS Syndrome: A Systematic Review of Case Reports.

Hospital pharmacy
2025

Specific clinical features define HLA-A∗32:01-positive vancomycin drug reaction with eosinophilia and systemic symptoms: A multi-institution cross-sectional study.

The journal of allergy and clinical immunology. In practice
2025

French national protocol for diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in adults and children.

Annales de dermatologie et de venereologie
2025

Apalutamide-Induced Drug-Induced Hypersensitivity Syndrome/Drug Reaction With Eosinophilia and Systemic Symptoms Involving Reactivation of Human Herpesvirus-6 and Cytomegalovirus: A Case Report.

The Journal of dermatology
2025

Janus kinase inhibitors in pediatric patients with corticosteroid-resistant drug reaction with eosinophilia and systemic symptoms.

The journal of allergy and clinical immunology. In practice
2025

Lady in Red: A Fatal Case of Drug Reaction With Eosinophilia and Systemic Symptoms.

Cureus
2025

Drug reaction with eosinophilia and systemic symptoms.

Internal and emergency medicine
2025

Olanzapine-induced Drug Reaction with Eosinophilia and Systemic Symptoms: Case Report and Review of the Literature.

Acta dermato-venereologica
2025

Mental health and psychosocial outcomes in survivors of severe cutaneous adverse reactions: a scoping review.

Clinical and experimental dermatology
2025

DRESS syndrome presenting with acute hypoxic respiratory failure and delayed eosinophilia.

BMJ case reports
2025

Abrocitinib in the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms.

American journal of therapeutics
2025

Carbamazepine-Induced DRESS Complicated by HLH and VBDS: A Case Report.

Journal of asthma and allergy
2025

Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome following Dalbavancin and Oritavancin Administration in a Patient with Osteomyelitis.

Case reports in dermatology
2025

Low-dose venlafaxine-induced erythema multiforme: a case report.

Journal of medical case reports
2025

Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025.

Allergology international : official journal of the Japanese Society of Allergology
2025

IL-5 Inhibitor Treatment in Drug Reaction With Eosinophilia and Systemic Symptoms.

JAMA dermatology
2025

Gabapentin for refractory pruritus in severe cutaneous adverse reactions.

JAAD case reports
2025

Atrial standstill due to eosinophilic myocarditis and drug reaction with eosinophilia and systemic symptoms.

HeartRhythm case reports
2025

Comparing immunopathogenesis of non-human immunodeficiency virus immune reconstitution inflammatory syndrome and immune-related adverse events: A prospective multicenter cohort study.

The Journal of dermatology
2025

[Hot Topics 2024 and 2025 in dermatology].

Revue medicale suisse
2025

Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries.

Pharmacoepidemiology and drug safety
2025

Histopathologic Features in Vancomycin-Associated Drug-Induced Hypersensitivity Syndrome.

Journal of cutaneous pathology
2025

[Dermatological conditions requiring intensive care treatment].

Dermatologie (Heidelberg, Germany)
2025

An unusually severe case of shiitake mushroom dermatitis with features of drug reaction with eosinophilia and systemic symptoms.

Skin health and disease
2025

Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA Database.

medRxiv : the preprint server for health sciences
2025

Decoding Beta-Lactam Cross-Reactivity - Longitudinal Patch Testing From 2000 to 2022.

Contact dermatitis
2025

Recommendations on how to proceed in case of suspected allergy to penicillin/β-lactam antibiotics: Position paper of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Society for Pediatric Allergology (GPA), Austrian Society for Allergology and Immunology (ÖGAI) and the Swiss Society for Allergology and Immunology (SGAI).

Allergologie select
2024

Severe Hypersensitivity Reactions with Oral Manifestations: Case Reports on Stevens-Johnson Syndrome and DRESS Syndrome.

Journal of pharmacy &amp; bioallied sciences
2025

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Retrospective Study of 51 Chinese Patients.

Clinical, cosmetic and investigational dermatology
2025

Hypereosinophilic Syndrome in a Patient With Complex Pulmonary Hypertension and Sjogren's Syndrome: A Case Report.

Cureus
2025

When Treatment Backfires: A Case Report of Sulfasalazine-Induced Hypersensitivity Syndrome in a Moroccan Patient With Crohn's Disease and Literature Review.

Cureus
2025

Diagnosing and Managing Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Amidst Remaining Uncertainty.

The journal of allergy and clinical immunology. In practice
2025

Rapid drug desensitization in seven patients with delayed hypersensitivity reactions to biologics and targeted therapies: Reason, successes, and failures.

Allergy and asthma proceedings
2025

Drug Reaction with Eosinophilia and Systemic Symptoms. Reply.

The New England journal of medicine
2025

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial.

JAMA dermatology
2025

Single-cell immunopathology of recurrent acute generalized exanthematous pustulosis associated with vancomycin.

The journal of allergy and clinical immunology. Global
2025

Severe Cutaneous Adverse Reactions Associated with Immune Checkpoint Inhibitors: A Systematic Review of Clinical Characteristics and Management.

Journal of cutaneous medicine and surgery
2025

Severe Cutaneous Adverse Reactions Following Vaccination: A Systematic Review and Meta-Analysis.

The journal of allergy and clinical immunology. In practice
2025

A Diagnostic Dilemma: Daptomycin-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome and Eosinophilic Pneumonia With Concurrent COVID-19.

Cureus
2025

[Exanthematic drug eruption].

Pathologie (Heidelberg, Germany)
2025

Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS.

Expert opinion on drug safety
2025

Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination.

British journal of clinical pharmacology
2025

Pediatric drug reaction with eosinophilia and systemic symptoms: Pharmacovigilance and prognosis.

Journal of the American Academy of Dermatology
2025

Impact of non-genetic factors on severe cutaneous adverse reactions and associated mortality in ESRD patients: Advancing clinical guidance.

The American journal of the medical sciences
2025

Vancomycin Drug Reaction with Eosinophilia and Systemic Symptoms: Meta-Analysis and Pharmacovigilance Study.

Journal of clinical medicine
2025

An Adverse Double-Hit by Pembrolizumab: A Case Report of Bullous Pemphigoid and Pneumonitis.

Journal of medical cases
2025

[Cas n#1. Drug reaction with eosinophilia and systemic symptoms].

Annales de pathologie
2024

DRESS (drug reaction with eosinophilia and systemic symptoms): a possible prolonged course with sequelae.

European journal of dermatology : EJD
2024

Drug reaction with eosinophilia and systemic symptoms with toxic epidermal necrolysis like rash in systemic sclerosis and overlapping sjogren's syndrome: A double trouble triggered by a herbal medicine.

Indian journal of dermatology, venereology and leprology
2025

Adult-Onset Still's Disease With Normal Ferritin Levels and Severe Sulfasalazine-Induced Probable Case of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Unique Presentation and Management Challenges.

Cureus
2025

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Associated With Celecoxib: A Case Report of a Rare Entity.

Cureus
2025

Drug Reaction With Eosinophilia and Systemic Symptoms to Vancomycin-Laden Cement Space: A Case Report.

Cureus
2025

Guidelines for the management of drug-induced hypersensitivity syndrome 2023.

The Journal of dermatology
2025

Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.

American journal of clinical dermatology
2025

Drug-Induced Hypersensitivity Syndrome/Drug Reaction With Eosinophilia and Systemic Symptoms With Reactivation of Human Herpesvirus-6 in a Liver Transplant Recipient.

Transplant infectious disease : an official journal of the Transplantation Society
2025

Leflunomide-induced drug reaction eosinophilia systemic symptoms and haemophagocytic lymphohistiocytosis overlap syndrome with rheumatoid arthritis.

BMJ case reports
2025

DRESS Is Not a Rare Complication during the Initial Treatment of Newly Diagnosed Multiple Myeloma: The Experience of Two Medical Institutes.

Acta haematologica
2025

Overlapping of DRESS and Stevens-Johnson syndrome due to first-line antituberculosis drugs: a case report.

Therapeutic advances in drug safety
2025

Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of antiseizure medications-An overview of clinical data.

Seizure
2025

Outcomes of ciclosporin treatment in paediatric patients with drug reaction with eosinophilia and systemic symptoms (DRESS): a retrospective cohort analysis.

Clinical and experimental dermatology
2025

A Rare Case of Fatal Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient with Rheumatoid Arthritis.

Current drug safety
2025

Pharmacogenomics predictors of aromatic antiepileptic drugs-induced SCARs in the Iraqi patients.

Heliyon
2025

An extremely prolonged case of drug reaction with eosinophilia and systemic symptoms (DRESS Syndrome) secondary to a penicillin-based antibiotic.

Anais brasileiros de dermatologia
2025

Post-marketing safety of antiseizure medications: Focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS).

Seizure
2025

DRESS Mimicking Flushing Syndrome Associated with Vancomycin: A Case Report.

Current drug safety
2024

DRESSed for distress: a case of allopurinol-induced DRESS syndrome.

Folia medica
2025

Patch Test-Positive Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Due to Cycloserine in Multidrug-Resistant Tuberculosis: A Case Report with a Review of the Literature.

The American journal of tropical medicine and hygiene
Ver todos os 679 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Reação medicamentosa com eosinofilia e sintomas sistêmicos.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Reação medicamentosa com eosinofilia e sintomas sistêmicos

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Correction: The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.
    Cureus· 2026· PMID 41878392mais citado
  2. The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.
    Cureus· 2026· PMID 41868441mais citado
  3. A case of steroid-induced mania following lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS): a cautionary tale.
    SAGE open medical case reports· 2026· PMID 41835807mais citado
  4. Tofacitinib Rescue for Refractory Drug-Induced Liver Injury With Severe DRESS: A Prospective Proof-of-Concept Study.
    Liver international : official journal of the International Association for the Study of the Liver· 2026· PMID 41823050mais citado
  5. A Diagnostic Pitfall: Carbamazepine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Masquerading As Angiotensin-Converting Enzyme Inhibitor Angioedema.
    Cureus· 2026· PMID 41822255mais citado
  6. Pediatric Severe Cutaneous Adverse Drug Reactions (SCARs) clinical characteristics and comparison of causality assesment tools and severity scoring systems in relation to clinical outcomes from a single center experience.
    Int Arch Allergy Immunol· 2026· PMID 41955167recente
  7. Pulmonary infiltrates as part of drug reaction with eosinophilia and systemic symptoms syndrome in a patient with pulmonary tuberculosis: a clinical conundrum.
    BMJ Case Rep· 2026· PMID 41927128recente
  8. Pembrolizumab and Nivolumab-Induced Late Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): A Case Report.
    Cureus· 2026· PMID 41924672recente
  9. Antiepileptic Drug-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Case Series.
    Cureus· 2026· PMID 41924668recente
  10. Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Following Carbamazepine Use in a Young Male With Psychiatric Comorbidities.
    Cureus· 2026· PMID 41924660recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:139402(Orphanet)
  2. MONDO:0015340(MONDO)
  3. GARD:13629(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q3931183(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Reação medicamentosa com eosinofilia e sintomas sistêmicos
Compêndio · Raras BR

Reação medicamentosa com eosinofilia e sintomas sistêmicos

ORPHA:139402 · MONDO:0015340
🇧🇷 Brasil SUS
Triagem
qPCR para deleção de SMN1 em sangue seco
PNTN
Fase 5
Incidência BR
1:10.000
Geral
Prevalência
Unknown
Herança
Not applicable
CID-10
T78.4 · Alergia não especificada
CID-11
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C1142139
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades